drugset / Trial / NCT00685230

Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

NCT00685230 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

There is no FDA approved therapy for the treatment of scorpion envenomation, Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care, midazolam, and faster-acting such that the need for transport of most rural patients will be eliminated and will reduce hospitalization time. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of scorpion sting envenomation. 2. The investigational antivenom is effective as treatment of scorpion sting envenomation.

Timeline

Start
2004-05
Primary completion
2005-08
Completion
2005-10

Outcome

Met primary endpoint

paper resolution of symptoms in all eight antivenom recipients versus one of seven placebo recipients within 4 hours after treatment (P=0.001). PMID 19439743 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Antivenin Centruroides (scorpion) equine immune F(ab)2 Protein / enzyme biologic — Intravenous

Indications